Mimedx (MDXG) Current Deferred Revenue (2011 - 2012)

Mimedx's (MDXG) quarterly Current Deferred Revenue came in at $6620.0 in Q1 2012, little changed quarter-over-quarter from $6620.0 in Q4 2011.

Analysis

Mimedx (MDXG) Current Deferred Revenue (2011 - 2012) Analysis & Trends

Mimedx has disclosed Current Deferred Revenue across 2 years of filings, most recently posting $6620.0 for Q1 2012.

In Q1 2012, Current Deferred Revenue changed N/A year-over-year to $6620.0; the TTM figure through Mar 2012 stood at $6620.0 (changed N/A YoY), while the FY2011 annual figure was $6620.0, changed N/A from the prior year.
Current Deferred Revenue came in at $6620.0 for Q1 2012 at Mimedx, roughly flat from $6620.0 in the prior quarter.
In the past five years, Current Deferred Revenue ranged from a high of $6620.0 in Q2 2011 to a low of $6620.0 in Q2 2011.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	181.19 Bn	175.58 Bn	7.27 Bn
2	Intuitive Surgical	127.77 Bn	122.55 Bn	1.96 Bn
3	Medtronic	117.13 Bn	108.31 Bn	6.34 Bn
4	Stryker	104.67 Bn	101.20 Bn	4.50 Bn
5	Boston Scientific	64.48 Bn	63.94 Bn	3.85 Bn
6	Edwards Lifesciences	49.97 Bn	45.72 Bn	1.35 Bn
7	Alcon	33.06 Bn	31.61 Bn	1.68 Bn
8	Dexcom	32.37 Bn	30.43 Bn	830.00 Mn
9	Steris	20.76 Bn	20.28 Bn	684.20 Mn
10	Mimedx	667.30 Mn	531.46 Mn	44.38 Mn

Historic Data

Download Data